R Squared’s Harvard Bioscience HBIO Stock Holding History

R Squared’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-574	Closed	-$12.1K	–	797
2024 Q4	$12.1K	Buy	+574	New	+$13.2K	0.01%	1086

Other funds holding HBIO

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

R Squared's HBIO Position: Q1 2025 in Review

R Squared sold out of Harvard Bioscience (HBIO) in Q1 2025, closing a stake of 574 shares — an estimated $12.1K sold.

R Squared first reported a position in HBIO in Q4 2024 and held it in 1 quarter. The position peaked at $12.1K in Q4 2024. 91 funds tracked by Wall St. Rank hold HBIO as of Q1 2025.

R Squared reported no remaining Harvard Bioscience position as of Q1 2025 after selling out during the quarter.
R Squared sold 574 Harvard Bioscience shares in Q1 2025, an estimated $12.1K.
R Squared first reported a position in Harvard Bioscience in Q4 2024 and held it in 1 quarter.
R Squared's Harvard Bioscience position peaked at $12.1K in Q4 2024.
91 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.